STOCK TITAN

[Form 4] KALA BIO, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Kala Bio insider Todd Bazemore, serving as Interim CEO, President and COO, reported a transaction on June 24, 2025 involving the sale of 4,058 shares of common stock at a weighted average price of $4.01 per share (range: $3.87-$4.12).

Key details of the transaction:

  • Sale was executed under a 10b5-1 trading plan established on November 10, 2020
  • Purpose: Cover tax withholding obligations related to RSU vesting from June 22, 2023 grant
  • Post-transaction holdings: 83,699 shares (including 35,732 unvested RSUs) held directly
  • Additional indirect ownership: 1 share held by son

The transaction was reported via Form 4 filing, signed by Mary Reumuth as attorney-in-fact on June 26, 2025, complying with SEC disclosure requirements for insider trading activity.

Todd Bazemore, dirigente interno di Kala Bio e attualmente CEO ad interim, Presidente e COO, ha comunicato una transazione avvenuta il 24 giugno 2025 relativa alla vendita di 4.058 azioni ordinarie a un prezzo medio ponderato di 4,01 $ per azione (con un intervallo da 3,87 $ a 4,12 $).

Dettagli principali della transazione:

  • La vendita è stata effettuata nell’ambito di un piano di trading 10b5-1 istituito il 10 novembre 2020
  • Finalità: copertura degli obblighi fiscali derivanti dalla ritenuta sulle azioni vincolate (RSU) maturate dalla concessione del 22 giugno 2023
  • Azioni detenute dopo la transazione: 83.699 (inclusi 35.732 RSU non ancora maturate) detenute direttamente
  • Ulteriore proprietà indiretta: 1 azione detenuta dal figlio

La transazione è stata comunicata tramite la presentazione del Modulo 4, firmato da Mary Reumuth come procuratore il 26 giugno 2025, in conformità con i requisiti di divulgazione della SEC sulle attività di trading degli insider.

Todd Bazemore, insider de Kala Bio y actual CEO interino, Presidente y COO, informó una transacción realizada el 24 de junio de 2025 que involucró la venta de 4,058 acciones ordinarias a un precio promedio ponderado de $4.01 por acción (rango: $3.87-$4.12).

Detalles clave de la transacción:

  • La venta se ejecutó bajo un plan de comercio 10b5-1 establecido el 10 de noviembre de 2020
  • Propósito: cubrir obligaciones fiscales relacionadas con la retención por la consolidación de RSU otorgadas el 22 de junio de 2023
  • Participaciones tras la transacción: 83,699 acciones (incluyendo 35,732 RSU no consolidadas) en propiedad directa
  • Propiedad indirecta adicional: 1 acción en manos de su hijo

La transacción se reportó mediante la presentación del Formulario 4, firmado por Mary Reumuth como apoderada el 26 de junio de 2025, cumpliendo con los requisitos de divulgación de la SEC para actividades de trading de insiders.

Kala Bio의 내부자이자 현재 임시 CEO, 사장 및 COO인 Todd Bazemore2025년 6월 24일에 보통주 4,058주를 주당 가중평균가격 $4.01 (범위: $3.87-$4.12)에 매도한 거래를 보고했습니다.

거래 주요 내용:

  • 2020년 11월 10일에 설정된 10b5-1 거래 계획에 따라 매도 실행
  • 목적: 2023년 6월 22일 부여된 RSU 베스팅 관련 세금 원천징수 의무 충당
  • 거래 후 보유 주식: 직접 보유 83,699주 (미베스팅 RSU 35,732주 포함)
  • 추가 간접 소유: 아들이 보유한 1주

이 거래는 2025년 6월 26일 Mary Reumuth가 법정대리인으로 서명한 Form 4 신고서를 통해 보고되었으며, SEC 내부자 거래 공시 요건을 준수합니다.

Todd Bazemore, initié chez Kala Bio et actuellement PDG par intérim, président et COO, a déclaré une transaction réalisée le 24 juin 2025 portant sur la vente de 4 058 actions ordinaires à un prix moyen pondéré de 4,01 $ par action (fourchette : 3,87 $ - 4,12 $).

Détails clés de la transaction :

  • La vente a été effectuée dans le cadre d’un plan de négociation 10b5-1 établi le 10 novembre 2020
  • Objectif : couvrir les obligations fiscales liées à la retenue à la source sur les actions RSU acquises à partir de la date d’attribution du 22 juin 2023
  • Actions détenues après la transaction : 83 699 (dont 35 732 RSU non acquises) détenues directement
  • Propriété indirecte supplémentaire : 1 action détenue par son fils

La transaction a été déclarée via le dépôt du formulaire 4, signé par Mary Reumuth en tant que mandataire, le 26 juin 2025, conformément aux exigences de divulgation de la SEC relatives aux opérations des initiés.

Todd Bazemore, Insider bei Kala Bio und derzeit Interim-CEO, Präsident und COO, meldete am 24. Juni 2025 eine Transaktion, bei der 4.058 Aktien des Stammkapitals zu einem gewichteten Durchschnittspreis von 4,01 $ pro Aktie (Spanne: 3,87 $–4,12 $) verkauft wurden.

Wichtige Details der Transaktion:

  • Verkauf erfolgte im Rahmen eines am 10. November 2020 eingerichteten 10b5-1-Handelsplans
  • Zweck: Deckung von Steuerabzugsverpflichtungen im Zusammenhang mit der RSU-Vesting aus der Zuteilung vom 22. Juni 2023
  • Bestände nach der Transaktion: 83.699 Aktien (einschließlich 35.732 nicht unverfallener RSUs) direkt gehalten
  • Zusätzlicher indirekter Besitz: 1 Aktie im Besitz des Sohnes

Die Transaktion wurde durch eine Form 4-Meldung am 26. Juni 2025 eingereicht, unterzeichnet von Mary Reumuth als Bevollmächtigte, und erfüllt die SEC-Offenlegungspflichten für Insiderhandel.

Positive
  • None.
Negative
  • None.

Todd Bazemore, dirigente interno di Kala Bio e attualmente CEO ad interim, Presidente e COO, ha comunicato una transazione avvenuta il 24 giugno 2025 relativa alla vendita di 4.058 azioni ordinarie a un prezzo medio ponderato di 4,01 $ per azione (con un intervallo da 3,87 $ a 4,12 $).

Dettagli principali della transazione:

  • La vendita è stata effettuata nell’ambito di un piano di trading 10b5-1 istituito il 10 novembre 2020
  • Finalità: copertura degli obblighi fiscali derivanti dalla ritenuta sulle azioni vincolate (RSU) maturate dalla concessione del 22 giugno 2023
  • Azioni detenute dopo la transazione: 83.699 (inclusi 35.732 RSU non ancora maturate) detenute direttamente
  • Ulteriore proprietà indiretta: 1 azione detenuta dal figlio

La transazione è stata comunicata tramite la presentazione del Modulo 4, firmato da Mary Reumuth come procuratore il 26 giugno 2025, in conformità con i requisiti di divulgazione della SEC sulle attività di trading degli insider.

Todd Bazemore, insider de Kala Bio y actual CEO interino, Presidente y COO, informó una transacción realizada el 24 de junio de 2025 que involucró la venta de 4,058 acciones ordinarias a un precio promedio ponderado de $4.01 por acción (rango: $3.87-$4.12).

Detalles clave de la transacción:

  • La venta se ejecutó bajo un plan de comercio 10b5-1 establecido el 10 de noviembre de 2020
  • Propósito: cubrir obligaciones fiscales relacionadas con la retención por la consolidación de RSU otorgadas el 22 de junio de 2023
  • Participaciones tras la transacción: 83,699 acciones (incluyendo 35,732 RSU no consolidadas) en propiedad directa
  • Propiedad indirecta adicional: 1 acción en manos de su hijo

La transacción se reportó mediante la presentación del Formulario 4, firmado por Mary Reumuth como apoderada el 26 de junio de 2025, cumpliendo con los requisitos de divulgación de la SEC para actividades de trading de insiders.

Kala Bio의 내부자이자 현재 임시 CEO, 사장 및 COO인 Todd Bazemore2025년 6월 24일에 보통주 4,058주를 주당 가중평균가격 $4.01 (범위: $3.87-$4.12)에 매도한 거래를 보고했습니다.

거래 주요 내용:

  • 2020년 11월 10일에 설정된 10b5-1 거래 계획에 따라 매도 실행
  • 목적: 2023년 6월 22일 부여된 RSU 베스팅 관련 세금 원천징수 의무 충당
  • 거래 후 보유 주식: 직접 보유 83,699주 (미베스팅 RSU 35,732주 포함)
  • 추가 간접 소유: 아들이 보유한 1주

이 거래는 2025년 6월 26일 Mary Reumuth가 법정대리인으로 서명한 Form 4 신고서를 통해 보고되었으며, SEC 내부자 거래 공시 요건을 준수합니다.

Todd Bazemore, initié chez Kala Bio et actuellement PDG par intérim, président et COO, a déclaré une transaction réalisée le 24 juin 2025 portant sur la vente de 4 058 actions ordinaires à un prix moyen pondéré de 4,01 $ par action (fourchette : 3,87 $ - 4,12 $).

Détails clés de la transaction :

  • La vente a été effectuée dans le cadre d’un plan de négociation 10b5-1 établi le 10 novembre 2020
  • Objectif : couvrir les obligations fiscales liées à la retenue à la source sur les actions RSU acquises à partir de la date d’attribution du 22 juin 2023
  • Actions détenues après la transaction : 83 699 (dont 35 732 RSU non acquises) détenues directement
  • Propriété indirecte supplémentaire : 1 action détenue par son fils

La transaction a été déclarée via le dépôt du formulaire 4, signé par Mary Reumuth en tant que mandataire, le 26 juin 2025, conformément aux exigences de divulgation de la SEC relatives aux opérations des initiés.

Todd Bazemore, Insider bei Kala Bio und derzeit Interim-CEO, Präsident und COO, meldete am 24. Juni 2025 eine Transaktion, bei der 4.058 Aktien des Stammkapitals zu einem gewichteten Durchschnittspreis von 4,01 $ pro Aktie (Spanne: 3,87 $–4,12 $) verkauft wurden.

Wichtige Details der Transaktion:

  • Verkauf erfolgte im Rahmen eines am 10. November 2020 eingerichteten 10b5-1-Handelsplans
  • Zweck: Deckung von Steuerabzugsverpflichtungen im Zusammenhang mit der RSU-Vesting aus der Zuteilung vom 22. Juni 2023
  • Bestände nach der Transaktion: 83.699 Aktien (einschließlich 35.732 nicht unverfallener RSUs) direkt gehalten
  • Zusätzlicher indirekter Besitz: 1 Aktie im Besitz des Sohnes

Die Transaktion wurde durch eine Form 4-Meldung am 26. Juni 2025 eingereicht, unterzeichnet von Mary Reumuth als Bevollmächtigte, und erfüllt die SEC-Offenlegungspflichten für Insiderhandel.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Bazemore Todd

(Last) (First) (Middle)
C/O KALA BIO, INC.
1167 MASSACHUSETTS AVENUE

(Street)
ARLINGTON MA 02476

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
KALA BIO, Inc. [ KALA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SEE REMARKS
3. Date of Earliest Transaction (Month/Day/Year)
06/24/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/24/2025 S 4,058(1) D $4.01(2) 83,699(3) D
Common Stock 1 I By son
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 10, 2020 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units ("RSUs") granted on June 22, 2023.
2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.87 to $4.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
3. Includes 35,732 unvested RSUs.
Remarks:
Interim Chief Executive Officer, President and Chief Operating Officer
/s/ Mary Reumuth, Attorney-in-Fact 06/26/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many shares of KALA stock did Todd Bazemore sell on June 24, 2025?

Todd Bazemore sold 4,058 shares of KALA common stock on June 24, 2025 at a weighted average price of $4.01 per share.

What is Todd Bazemore's current position at KALA Bio?

Todd Bazemore serves as Interim Chief Executive Officer, President and Chief Operating Officer of KALA Bio, Inc.

Why did KALA's Todd Bazemore sell shares in June 2025?

The sale was made pursuant to a 10b5-1 trading plan adopted on November 10, 2020 to cover tax withholding obligations related to the vesting and settlement of restricted stock units (RSUs) granted on June 22, 2023.

How many KALA shares does Todd Bazemore own after the June 24, 2025 transaction?

Following the transaction, Todd Bazemore owns 83,699 shares directly (including 35,732 unvested RSUs) and 1 share indirectly through his son.

What was the price range for KALA shares sold by Todd Bazemore?

The shares were sold in multiple transactions at prices ranging from $3.87 to $4.12 per share, with a weighted average price of $4.01.
Kala Pharmaceuticals Inc

NASDAQ:KALA

KALA Rankings

KALA Latest News

KALA Latest SEC Filings

KALA Stock Data

25.94M
5.79M
4.12%
58.58%
4.66%
Biotechnology
Pharmaceutical Preparations
Link
United States
ARLINGTON